By BFN News | 09:50 AM | Thursday 22 April, 2021 Renalytix AI plc has announced that the United States government has granted the company a 10-year Governmentwide Acquisition Contract (GWAC) to provide KidneyIntelX early-stage kidney disease bioprognostic? testing services.
The contract, offered through the General Services Administration (GSA), covers laboratory testing services that can be provided through more than 140 US government departments, agencies and affiliates, including the US Veterans Administration (VA), Department of Defense (DoD) military branches (Army, Navy, Air Force, and Marines), and Indian Health Services (IHS).
Effective as of April 15, 2021, the contract has a five-year term with a five-year extension option, and is structured as an Indefinite Delivery, Indefinite Quantity (IDIQ) contract providing for an unlimited quantity of services over the contract term.
Home / Top News / Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics
Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics
Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations
NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) The Centers for Medicaid & Medicare (CMS) announced the establishment of the Medicare Coverage of Innovative Technology (MCIT) pathway (
RIN: 0938-AT88), to provide a coverage pathway for Medicare beneficiaries nationwide to have faster access to new, innovative medical devices and diagnostic tests designated under the Breakthrough Device review program and with market authorization by the U.S. Food and Drug Administration (FDA). Under MCIT, national Medicare coverage can become effective on the date of FDA approval or clearance of a breakthr
About RenalytixAI RenalytixAI (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company s lead product is KidneyIntelX.com (visit www.kidneyintelx.com ) which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential for KidneyIntelX to receive regula
Local small businesses get state boost for their COVID-19 innovations gazettextra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazettextra.com Daily Mail and Mail on Sunday newspapers.